340 related articles for article (PubMed ID: 19426684)
1. The mechanism of cytotoxicity and DNA adduct formation by the anticancer drug ellipticine in human neuroblastoma cells.
Poljaková J; Eckschlager T; Hrabeta J; Hrebacková J; Smutný S; Frei E; Martínek V; Kizek R; Stiborová M
Biochem Pharmacol; 2009 May; 77(9):1466-79. PubMed ID: 19426684
[TBL] [Abstract][Full Text] [Related]
2. Analysis of covalent ellipticine- and doxorubicin-derived adducts in DNA of neuroblastoma cells by the ³²P-postlabeling technique.
Stiborova M; Poljakova J; Eckschlager T; Kizek R; Frei E
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2012 Jun; 156(2):115-21. PubMed ID: 22837132
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxicity of and DNA adduct formation by ellipticine in human U87MG glioblastoma cancer cells.
Martinkova E; Dontenwill M; Frei E; Stiborova M
Neuro Endocrinol Lett; 2009; 30 Suppl 1():60-6. PubMed ID: 20027146
[TBL] [Abstract][Full Text] [Related]
4. Anticancer agent ellipticine combined with histone deacetylase inhibitors, valproic acid and trichostatin A, is an effective DNA damage strategy in human neuroblastoma.
Poljakova J; Hrebackova J; Dvorakova M; Moserova M; Eckschlager T; Hrabeta J; Göttlicherova M; Kopejtkova B; Frei E; Kizek R; Stiborova M
Neuro Endocrinol Lett; 2011; 32 Suppl 1():101-16. PubMed ID: 22167207
[TBL] [Abstract][Full Text] [Related]
5. The anticancer drug ellipticine forms covalent DNA adducts, mediated by human cytochromes P450, through metabolism to 13-hydroxyellipticine and ellipticine N2-oxide.
Stiborová M; Sejbal J; Borek-Dohalská L; Aimová D; Poljaková J; Forsterová K; Rupertová M; Wiesner J; Hudecek J; Wiessler M; Frei E
Cancer Res; 2004 Nov; 64(22):8374-80. PubMed ID: 15548707
[TBL] [Abstract][Full Text] [Related]
6. DNA adduct formation by the anticancer drug ellipticine in human leukemia HL-60 and CCRF-CEM cells.
Poljaková J; Frei E; Gomez JE; Aimová D; Eckschlager T; Hrabeta J; Stiborová M
Cancer Lett; 2007 Jul; 252(2):270-9. PubMed ID: 17306925
[TBL] [Abstract][Full Text] [Related]
7. Cytochrome P450- and peroxidase-mediated oxidation of anticancer alkaloid ellipticine dictates its anti-tumor efficiency.
Stiborová M; Rupertová M; Frei E
Biochim Biophys Acta; 2011 Jan; 1814(1):175-85. PubMed ID: 20576524
[TBL] [Abstract][Full Text] [Related]
8. Ellipticine-loaded apoferritin nanocarrier retains DNA adduct-based cytochrome P450-facilitated toxicity in neuroblastoma cells.
Indra R; Černá T; Heger Z; Hraběta J; Wilhelm M; Dostálová S; Lengálová A; Martínková M; Adam V; Eckschlager T; Schmeiser HH; Arlt VM; Stiborová M
Toxicology; 2019 May; 419():40-54. PubMed ID: 30914192
[TBL] [Abstract][Full Text] [Related]
9. Formation and persistence of DNA adducts of anticancer drug ellipticine in rats.
Stiborová M; Rupertová M; Aimová D; Ryslavá H; Frei E
Toxicology; 2007 Jul; 236(1-2):50-60. PubMed ID: 17482743
[TBL] [Abstract][Full Text] [Related]
10. The anticancer drug ellipticine is a potent inducer of rat cytochromes P450 1A1 and 1A2, thereby modulating its own metabolism.
Aimová D; Svobodová L; Kotrbová V; Mrázová B; Hodek P; Hudecek J; Václavíková R; Frei E; Stiborová M
Drug Metab Dispos; 2007 Oct; 35(10):1926-34. PubMed ID: 17656468
[TBL] [Abstract][Full Text] [Related]
11. Rat microsomes activating the anticancer drug ellipticine to species covalently binding to deoxyguanosine in DNA are a suitable model mimicking ellipticine bioactivation in humans.
Stiborová M; Stiborová-Rupertová M; Borek-Dohalská L; Wiessler M; Frei E
Chem Res Toxicol; 2003 Jan; 16(1):38-47. PubMed ID: 12693029
[TBL] [Abstract][Full Text] [Related]
12. The comparison of cytotoxicity of the anticancer drugs doxorubicin and ellipticine to human neuroblastoma cells.
Poljaková J; Eckschlager T; Hřebačková J; Hraběta J; Stiborová M
Interdiscip Toxicol; 2008 Sep; 1(2):186-9. PubMed ID: 21218110
[TBL] [Abstract][Full Text] [Related]
13. Ellipticine cytotoxicity to cancer cell lines - a comparative study.
Stiborová M; Poljaková J; Martínková E; Bořek-Dohalská L; Eckschlager T; Kizek R; Frei E
Interdiscip Toxicol; 2011 Jun; 4(2):98-105. PubMed ID: 21753906
[TBL] [Abstract][Full Text] [Related]
14. Vacuolar-ATPase-mediated intracellular sequestration of ellipticine contributes to drug resistance in neuroblastoma cells.
Hrabeta J; Groh T; Khalil MA; Poljakova J; Adam V; Kizek R; Uhlik J; Doktorova H; Cerna T; Frei E; Stiborova M; Eckschlager T
Int J Oncol; 2015 Sep; 47(3):971-80. PubMed ID: 26134421
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of ellipticine-mediated resistance in UKF-NB-4 neuroblastoma cells.
Procházka P; Libra A; Zemanová Z; Hřebačková J; Poljaková J; Hraběta J; Bunček M; Stiborová M; Eckschlager T
Cancer Sci; 2012 Feb; 103(2):334-41. PubMed ID: 22040216
[TBL] [Abstract][Full Text] [Related]
16. Oxidation pattern of the anticancer drug ellipticine by hepatic microsomes - similarity between human and rat systems.
Stiborová M; Borek-Dohalská L; Aimová D; Kotrbová V; Kukacková K; Janouchová K; Rupertová M; Ryslavá H; Hudecek J; Frei E
Gen Physiol Biophys; 2006 Sep; 25(3):245-61. PubMed ID: 17197724
[TBL] [Abstract][Full Text] [Related]
17. Cytochromes P450 reconstituted with NADPH: P450 reductase mimic the activating and detoxicating metabolism of the anticancer drug ellipticine in microsomes.
Kotrbová V; Aimová D; Brezinová A; Janouchová K; Poljaková J; Frei E; Stiborová M
Neuro Endocrinol Lett; 2006 Dec; 27 Suppl 2():18-22. PubMed ID: 17159771
[TBL] [Abstract][Full Text] [Related]
18. Mammalian peroxidases activate anticancer drug ellipticine to intermediates forming deoxyguanosine adducts in DNA identical to those found in vivo and generated from 12-hydroxyellipticine and 13-hydroxyellipticine.
Stiborová M; Poljaková J; Ryslavá H; Dracínský M; Eckschlager T; Frei E
Int J Cancer; 2007 Jan; 120(2):243-51. PubMed ID: 17066455
[TBL] [Abstract][Full Text] [Related]
19. Oxidation of an antitumor drug ellipticine by peroxidases.
Poljaková J; Forsterová K; Sulc M; Frei E; Stiborová M
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2005 Dec; 149(2):449-53. PubMed ID: 16601808
[TBL] [Abstract][Full Text] [Related]
20. Role of hepatic cytochromes P450 in bioactivation of the anticancer drug ellipticine: studies with the hepatic NADPH:cytochrome P450 reductase null mouse.
Stiborová M; Arlt VM; Henderson CJ; Wolf CR; Kotrbová V; Moserová M; Hudecek J; Phillips DH; Frei E
Toxicol Appl Pharmacol; 2008 Feb; 226(3):318-27. PubMed ID: 17976674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]